Roth starts Crinetics Pharma at buy; PT $37

Roth Capital Partners launched coverage of Crinetics Pharmaceuticals (NASDAQ:CRNX) with a “buy” rating and $37 price target. The stock closed at $21.91 on Dec. 20.

Crinetics is a clinical-stage pharmaceutical company with one-of-a-kind endocrine G-protein coupled receptor discovery platform technology that has already generated a 6,000-molecule library, writes analyst Yasmeen Rahimi. 

With the aid of the platform, she said the company has identified four molecules: two in the clinic and two preclinical. Lead drug candidate, CRN00808, is a new class of oral selective non-peptide somatostatin receptor 2 (SST2) agonist, which is currently in Phase 2 testing for the treatment of acromegaly, a hormonal disorder that results from the production of too much growth hormone, with topline data expected in 2020. 

The company’s second asset is CRN01941, also an oral non-peptide SST2 agonist, and in Phase 1 development, with data expected in early 2020 for treatment of neuroendocrine tumors. 

With sufficient capital to last through the first half of 2021, “we believe positive proof-of-concept data in humans for CRN01941 is likely to drive the stock upwards while bringing several large Pharma partners to the table,” Ms. Rahimi said.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.